qq

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

一 |       香港8月21日电（黄茜恬）《香港文学》刊行500期座谈会暨新书发布会21日在香港举行，近百位作家、学者和文化出版界人士出席。    (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。

二 |   8月21日，在《香港文学》刊行500期座谈会暨新书发布会上，嘉宾为新书揭幕。

三 | 发  《香港文学》总编辑游江说：“《香港文学》自创刊以来始终扎根香港、面向世界。

四 | 在40余年的时光里，一直以文字承载着生命的厚度与文学的重量。”香港文学出版社社长李国红表示，刊物将秉持“立足本土，兼顾海内外；不问流派，但求作品素质”的宗旨继续耕耘。  香港学者黄维梁感叹，《香港文学》刊行500期是了不起的马拉松长跑纪录。作家秦岭雪、梅子、江扬、周蜜蜜等细数刊物举办全球华文创作大赛、学术研讨会等新猷。祖籍福建金门的作家东瑞提到《香港文学》早前推出“台湾文学专号”，对港台文学交流意义重大。来自澳门的作家周江明认为《香港文学》不仅是香港的文化名片，更是连结港澳、沟通世界的桥梁。  刊物近年来与招商局合作，每年编辑出版两本《香港文学·校园文学作品集》。

五 | 1872香港少年作家班导师、作家赵阳认为，《香港文学》始终把握时代脉搏，为香港文学的发展注入经久不衰的活力。中文教师、作家蒲苇也从校园文学角度出发，肯定刊物近年推动校园文学创作等举措。

六 |   随后举办的新书发布会重点推介香港文学出版社今年出版的一系列出版物，包括刘以鬯旅游小说集《异地·异景·异情》、《香港文学》创刊号精装复刻本等。  《香港文学》创刊于1985年1月，作为香港历史最悠久的纯文学刊物，见证了香港文学的传承与发展，也是世界华文文学创作与研究的重要平台。

Current article:http://7l28k4d.tourunbiaodubaicubangninan.shop/news/20260826_5369.html

Published on:03:09:40